Potential risks include the unwanted spread of NGF to non-targeted brain regions, leading to side effects such as pain and weight loss. The trial's focus is on safety, and the efficacy of NGF gene therapy in slowing AD progression will require further investigation in Phase II trials. The gene discussed is NGF; the disease is Alzheimer disease.